Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692377 | 0.98 | CNR1 (0.46) | CNR1EPHX2FAAHCNR2 | |
| SCHEMBL3698157 | 0.96 | PRCP (0.40) | CNR1EPHX2 | |
| SCHEMBL3693935 | 0.96 | PRCP (0.40) | CNR1EPHX2 | |
| SCHEMBL3693937 | 0.94 | CNR1 (0.39) | CNR1 | |
| SCHEMBL3698159 | 0.94 | CNR1 (0.39) | CNR1 | |
| SCHEMBL3424209 | 0.83 | TBXAS1 (0.38) | — | |
| SCHEMBL3425992 | 0.82 | LTA4H (0.34) | — | |
| SCHEMBL3424211 | 0.82 | TBXAS1 (0.39) | — | |
| SCHEMBL3426000 | 0.80 | CHRM5 (0.35) | — | |
| SCHEMBL3427938 | 0.77 | APP (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851615-B2 | Lipophilic conjugated iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080108801-A1 | Lipophilic Conjugated iRNA Agents | BANK OF AMERICA, N.A. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108801-A1 | Lipophilic Conjugated iRNA Agents | NCL, PARP1, HNRNPA1 | CNR1 2569/4885EPHX2 4193/4885FAAH 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.